Literature DB >> 15878339

The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.

Susana Salceda1, Tenny Tang, Muriel Kmet, Andrei Munteanu, Malavika Ghosh, Roberto Macina, Wenhui Liu, Glenn Pilkington, Jackie Papkoff.   

Abstract

B7-H4 protein is expressed on the surface of a variety of immune cells and functions as a negative regulator of T cell responses. We independently identified B7-H4 (DD-O110) through a genomic effort to discover genes upregulated in tumors and here we describe a new functional role for B7-H4 protein in cancer. We show that B7-H4 mRNA and protein are overexpressed in human serous ovarian cancers and breast cancers with relatively little or no expression in normal tissues. B7-H4 protein is extensively glycosylated and displayed on the surface of tumor cells and we provide the first demonstration of a direct role for B7-H4 in promoting malignant transformation of epithelial cells. Overexpression of B7-H4 in a human ovarian cancer cell line with little endogenous B7-H4 expression increased tumor formation in SCID mice. Whereas overexpression of B7-H4 protected epithelial cells from anoikis, siRNA-mediated knockdown of B7-H4 mRNA and protein expression in a breast cancer cell line increased caspase activity and apoptosis. The restricted normal tissue distribution of B7-H4, its overexpression in a majority of breast and ovarian cancers and functional activity in transformation validate this cell surface protein as a new target for therapeutic intervention. A therapeutic antibody strategy aimed at B7-H4 could offer an exciting opportunity to inhibit the growth and progression of human ovarian and breast cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878339     DOI: 10.1016/j.yexcr.2005.01.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  74 in total

1.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

2.  The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium.

Authors:  Guoning Guo; Yongjun Shang; Guoyan Zhu; Xiaoren Bao; Shiwei Xu; Yongwen Chen
Journal:  Clin Rheumatol       Date:  2011-07-22       Impact factor: 2.980

3.  Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Authors:  Jenessa B Smith; Evripidis Lanitis; Denarda Dangaj; Elizabeth Buza; Mathilde Poussin; Caitlin Stashwick; Nathalie Scholler; Daniel J Powell
Journal:  Mol Ther       Date:  2016-07-21       Impact factor: 11.454

4.  B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.

Authors:  Amy E Krambeck; R Houston Thompson; Haidong Dong; Christine M Lohse; Eugene S Park; Susan M Kuntz; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-23       Impact factor: 11.205

Review 5.  T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Authors:  Yael S Barach; Jun Sik Lee; Xingxing Zang
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

6.  B7-H4-deficient mice display augmented neutrophil-mediated innate immunity.

Authors:  Gefeng Zhu; Mathew M Augustine; Takeshi Azuma; Liqun Luo; Sheng Yao; Sudarshan Anand; A Cecilia Rietz; Jiaqiang Huang; Haiying Xu; Andrew S Flies; Sarah J Flies; Koji Tamada; Marco Colonna; Jan M A van Deursen; Lieping Chen
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

7.  B7-H4 downregulation induces mitochondrial dysfunction and enhances doxorubicin sensitivity via the cAMP/CREB/PGC1-α signaling pathway in HeLa cells.

Authors:  Hyoung Kyu Kim; In-Sung Song; Sun Young Lee; Seung Hun Jeong; Sung Ryul Lee; Hye Jin Heo; Vu Thi Thu; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Dae Hun Jeong; Young Nam Kim; Jin Han
Journal:  Pflugers Arch       Date:  2014-12       Impact factor: 3.657

8.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 9.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

Review 10.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.